Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Madrigal Pharmaceuticals, Inc. - Common Stock
(NQ:
MDGL
)
436.87
-54.62 (-11.11%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 19, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Madrigal Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
The 3 Best Biotech Stocks to Buy Now: September 2023
↗
September 04, 2023
With the biotech sector looking poised to continue its rally further, investors would do well to buy these stocks to capitalize.
Via
InvestorPlace
3 Biotech Stocks That Wall Street Analysts Can’t Get Enough Of
↗
August 30, 2023
Worries about biotech stocks are way overdone, so the sector should make a big comeback in the coming months.
Via
InvestorPlace
The 3 Most Promising Pharma Stocks to Own Now
↗
August 30, 2023
A pillar to economic growth in a defensive area, these promising pharma stocks are set to rise and give investors one bullish ride.
Via
InvestorPlace
3 Biotechs Compete for the Same $108-Billion-Dollar Market. Are They a Buy?
↗
August 23, 2023
NASH treatments are projected to be one of the most sought-after indications in the coming years.
Via
The Motley Fool
Looking for the Next Big Biopharma Stock? These 4 Letters Are 1 Big Clue Where to Find It
↗
August 23, 2023
NASH is a surprisingly common ailment, and the first treatments are on the way.
Via
The Motley Fool
Why Madrigal Pharmaceuticals Stock Is Marching Higher Today
↗
May 24, 2023
Two key tailwinds appear to be lifting the stock today.
Via
The Motley Fool
Analyst Expectations for Madrigal Pharmaceuticals's Future
↗
May 16, 2023
Via
Benzinga
Why Madrigal Pharmaceuticals Stock Is Slumping Today
↗
May 09, 2023
The biotech's shares briefly plunged following its 2023 Q1 earnings report.
Via
The Motley Fool
Ozempic Could Have a New Multibillion-Dollar Market Opportunity. Is Novo Nordisk Stock a No-Brainer Buy?
↗
August 02, 2023
Novo Nordisk received some good news in a recent physician survey.
Via
The Motley Fool
Madrigal Stock Pops As It Makes Inroads Into What Could Be A $160 Billion Market
↗
June 30, 2023
Madrigal is working on gaining FDA approval for what could be the first NASH treatment.
Via
Investor's Business Daily
Terns Pharmaceuticals Is "Attractively Priced" Despite Pressure From Eli Lilly's Obesity Data, Analyst Says
↗
June 28, 2023
Tuesday, Terns Pharmaceuticals Inc (NASDAQ: TERN) shares lost more than 25% of their value due to investor pressure it faced after Eli Lilly And Co (NYSE: LLY) announced data from retatrutide that was...
Via
Benzinga
2 Growth Stocks That Doubled in 2023 and Could Shoot 55% to 87% Higher, According to Wall Street
↗
May 30, 2023
Recent moves to the upside could be the beginning of a much larger bull run.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
↗
May 26, 2023
Via
Benzinga
Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) is a Leading Gainer in 3/17 Morning Trading
March 17, 2023
Via
Investor Brand Network
Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
June 27, 2023
Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health.
Via
Benzinga
Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) Making Surprising Moves in Tuesday Session
May 23, 2023
Via
Investor Brand Network
Intercept Crashes As FDA Advisors Deliver The Likely Deathblow For Its Highly Watched NASH Drug
↗
May 22, 2023
The FDA's advisors voted resoundingly against accelerated approval for obeticholic acid.
Via
Investor's Business Daily
Why These 3 Nasdaq Stocks Buckled Today
↗
May 16, 2023
The FTC's decision to sue to block a high-profile merger is weighing on biotech valuations today.
Via
The Motley Fool
Viking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 Trial
↗
May 16, 2023
Ligand Pharmaceuticals Incorporated's (NASDAQ: LGND) partner Viking Therapeutics Inc (NASDAQ: VKTX) announced positive topline results from its Phase 2b trial of VK2809 in
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
↗
April 28, 2023
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
↗
April 27, 2023
Via
Benzinga
3 Biotechs That Might Get Bought Out in 2023
↗
April 26, 2023
Biotech is expected to be a hotbed of mergers and acquisitions this year.
Via
The Motley Fool
Why Madrigal Pharmaceuticals Stock Gained 20% This Week
↗
April 20, 2023
Two key tailwinds fueled a surge in the biotech's share price this week.
Via
The Motley Fool
Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names
↗
April 20, 2023
Where is the current bull market? All indications would be that it's in biotech! The broader market is not really moving. There have been plenty of attention-grabbing headlines, and earnings season is...
Via
Benzinga
Why Top 1% Biotech Madrigal Pharmaceuticals Just Surged Closer To A Breakout
↗
April 18, 2023
Shares are closing in on a buy point after retaking their 50-day moving average.
Via
Investor's Business Daily
Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) Making Surprising Moves in Tuesday Session
April 18, 2023
Via
Investor Brand Network
5 Best Stocks to Buy in April
↗
April 01, 2023
These powerful trends should yield stellar returns for investors in April and beyond.
Via
The Motley Fool
Up 463%, This Sizzling Growth Stock Could Have a Lot More Room to Run
↗
March 29, 2023
Viking Therapeutics stock might in the midst of a historic run.
Via
The Motley Fool
Is Viking Therapeutics a Smart Buy on the Dip?
↗
March 27, 2023
The stock recently fell around 25% for reasons that had nothing to do with its lead program.
Via
The Motley Fool
Want Diversified Upside in Biotechnology? Check out LABU
March 22, 2023
Watch the Direxion Daily S&P 500 Biotech Bull 3X Shares (NYSEARCA: LABU) if you want a speculative play in the biotechnology industry with amplified volatility.
Via
MarketBeat
Topics
ETFs
Stocks
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
